Study of IparomlimabTuvorlimab QL1706 with Modified TPF Regimen for Induction Therapy in Adults with Locally Advanced Nasopharyngeal Carcinoma

What this Trial Is About

Researchers are evaluating a treatment approach for patients with locally advanced nasopharyngeal carcinoma who have not received prior systemic therapy. This prospective, open-label, multicenter, single-arm clinical study aims to assess the effects of combining IparomlimabTuvorlimab QL-1706 with a modified TPF chemotherapy regimen followed by standard concurrent chemoradiotherapy. The study is led by The First Affiliated Hospital of Xiamen University and involves 30 patients across three centers. Participants will receive three cycles of induction therapy including Albumin-bound paclitaxel, cisplatin, S1 oral medication based on body surface area, and IparomlimabTuvorlimab administered once per cycle. Each cycle lasts 21 days. Afterward, patients will undergo two cycles of concurrent chemotherapy with cisplatin and a full course of intensity-modulated radiotherapy IMRT as per clinical standards. During the study, patients will be closely monitored for complete response rates after induction therapy, overall response rates, treatment-related side effects, progression-free survival, and overall survival for up to two years post-treatment. Assessments include imaging to measure tumor response and regular clinical evaluations. Total participation involves initial enrollment through the end of treatment and follow-up monitoring for two years.

Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC